

SUPPLEMENTARY TABLES

Supplementary Table 1. Antibiotic classes received and risk for healthcare facility-onset CDI in the ICU.

Antibiotic Class	CDI/Total Exposed (%)	Adjusted HR* (95% CI)
No antibiotics	32/5,895 (0.5)	Ref
Aminoglycosides	53/1,909 (2.8)	1.08 (0.77-1.52)
Aminopenicillins	7/301 (2.3)	1.03 (0.48-2.21)
Aztreonam	14/560 (2.5)	1.23 (0.69-2.19)
Carbapenems	34/1,350 (2.5)	0.84 (0.55-1.30)
Cephalosporins (all)	87/6,179 (1.4)	0.77 (0.56-1.07)
Clindamycin	5/254 (2.0)	0.97 (0.40-2.38)
Daptomycin	4/125 (3.2)	1.19 (0.43-3.33)
Fluoroquinolones	25/950 (2.6)	1.03 (0.67-1.59)
Linezolid	13/639 (2.0)	0.67 (0.35-1.27)
Macrolides	26/1,525 (1.7)	0.69 (0.44-1.08)
β -lactams/ β -lactamase inhibitors	147/5,350 (2.8)	1.61 (1.21-2.15)
Trimethoprim-sulfamethoxazole	15/879 (1.7)	0.86 (0.49-1.48)
Vancomycin IV	172/6,200 (2.8)	1.42 (1.05-1.92)

ICU, intensive care unit; CDI, *C. difficile* infection; HR, hazard ratio; CI, confidence interval. *Adjusted for creatinine, albumin, Charlson Comorbidity Index, mechanical ventilation, hemodialysis, ICU type, and proton pump inhibitors.

Supplementary Table 2. Relationship between PPIs and risk for healthcare facility-onset CDI in the ICU in a subset of the study cohort, stratified by concurrent exposure to antibiotics.

PPI Exposure Categories, in Defined Daily Dose*	Adjusted HR* (95% CI)
Without concurrent antibiotics	
None	Ref
≤ 1 defined daily dose	1.48 (0.40-5.51)
>1 to <2 defined daily dose	1.57 (0.54-4.58)
≥2 defined daily dose	0.84 (0.18-3.88)
With concurrent antibiotics	
None	Ref
≤ 1 defined daily dose	0.26 (0.15-0.45)
>1 to <2 defined daily dose	0.39 (0.27-0.56)
≥2 defined daily dose	0.45 (0.30-0.68)

HR, hazard ratio; PPI, proton pump inhibitor; ICU, intensive care unit; CDI, *C. difficile* infection; CI, confidence interval. *A defined daily dose of 1.0 is the equivalent of a mean daily dose of 20 mg omeprazole. **Adjusted for creatinine, albumin, Charlson Comorbidity Index, mechanical ventilation, hemodialysis, ICU type.